Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society.
I Department of Cardiology of the Poznan University of Medical Sciences. ewa.straburzynska-migaj@skpp.edu.pl.
Ewa
E
Straburzyńska-Migaj
Jadwiga
J
Nessler
Marcin
M
Gruchała
Karol
K
Kamiński
Małgorzata
M
Lelonek
Przemysław
P
Leszek
Katarzyna
K
Mizia-Stec
Piotr
P
Rozentryt
Andrzej
A
Gackowski
Adrian
A
Gwizdała
Ewa A
EA
Jankowska
Piotr
P
Ponikowski
D000613:Aminobutyrates / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D002309:Cardiology / Q000592:standards; D004338:Drug Combinations; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D010346:Patient Care Management; D011044:Poland; D020127:Recovery of Function; D012955:Societies, Medical / Q000592:standards; D013318:Stroke Volume; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D000068756:Valsartan
D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; C549068:sacubitril and valsartan sodium hydrate drug combination